Iryna Drozd/iStock via Getty Images
Tyra Biosciences (NASDAQ:TYRA) said the FDA has granted Rare Pediatric Disease Designation to its drug candidate TYRA-300 in the treatment of achondroplasia, the most common form of dwarfism.
The company plans to submit an application to the FDA in the second half of 2024 to initiate a Phase 2 study of the drug in the treatment of children with achondroplasia.